Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Organovo Holdings Inc. - news published 133 - readings 3.073

BACK

Organovo Holdings Inc.

Organovo Provides Business Update (Form 8-K)

Organovo Provides Business Update San Diego, CA - March 27, 2025 - Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business update. With the closing of the sale of its FXR Program to Lilly (NYSE:LL ...

27.03.2025

Organovo Holdings Inc.

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company (Form 8-K)

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company San Diego, CA - March 25, 2025 - Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its ...

26.03.2025

Organovo Holdings Inc.

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Organovo Holdings Inc. published this content on March 25, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 25, 2025 at 15:37:33.683 .

25.03.2025

Organovo Holdings Inc.

CERTIFICATE OF THIRD AMENDMENTTO THECERTIFICATE OF INCORPORATIONOFORGANOVO HOLDINGS, INC (Form 8-K)

CERTIFICATE OF THIRD AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ORGANOVO HOLDINGS, INC. Organovo Holdings, Inc. (the "corporation"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "DGCL"), does hereby certify that: A. The name of this corporation is Organovo Holdings, Inc. and the ...

21.03.2025

Organovo Holdings Inc.

Organovo Announces Reverse Stock Split

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Organovo Holdings Inc. published this content on March 19, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 19, 2025 at 12:33:36.088 .

19.03.2025

Organovo Holdings Inc.

Organovo Announces Reverse Stock Split (Form 8-K)

Organovo Announces Reverse Stock Split SAN DIEGO, March 19, 2025 -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p ...

19.03.2025

Organovo Holdings Inc.

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Organovo Holdings Inc. published this content on March 06, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 06, 2025 at 13:14:26.672 .

06.03.2025

Organovo Holdings Inc.

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises (Form 8-K)

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises San Diego, CA - March 6, 2025 - Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional sh ...

06.03.2025

Organovo Holdings Inc.

Supplemental Prospectus (Form 424B5)

Filed Pursuant to Rule 424(b)(5) Registration No. 333-276722 AMENDMENT NO. 1 dated February 26, 2025 (To Prospectus dated February 8, 2024) Up to $5,311,508 Common Stock This Amendment No. 1 to Prospectus (this "Amendment") amends and supplements the information in the prospectus, dated February 8, 2024, filed as part of our registration statement on Form S-3 (File N ...

26.02.2025

Organovo Holdings Inc.

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company (Form 8-K)

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company San Diego, CA - February 25, 2025 - Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly and Company (NYSE ...

25.02.2025

Organovo Holdings Inc.

Quarterly Report for Quarter Ending December 31, 2024 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 ...

19.02.2025

Organovo Holdings Inc.

Late Filing Notice (Form NT 10-Q)

SEC FILE NUMBER 001-35996 CUSIP NUMBER 68620A203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ...

14.02.2025

Organovo Holdings Inc.

Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on July 18, 2024, Organovo Holdings, Inc., a Delaware corporation (the "Company"), received a written notice (the "Notice") from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (" ...

17.01.2025

Organovo Holdings Inc.

Initial Statement of Beneficial Ownership (Form 3)

Ownership Submission FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 (Print or T ...

08.01.2025

Organovo Holdings Inc.

Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 30, 2024, the Board of Directors of Organovo Holdings, Inc. (the "Company") appointed Norman Staskey, age 55, as the Company's President, Chief Financial Officer and Principal Financial Officer, effec ...

31.12.2024

Organovo Holdings Inc. - news published 133 - readings 3.073

Organovo Holdings Inc.

Organovo Provides Business Update (Form 8-K)

Organovo Holdings Inc.

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company (Form 8-K)

Organovo Holdings Inc.

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Organovo Holdings Inc.

CERTIFICATE OF THIRD AMENDMENTTO THECERTIFICATE OF INCORPORATIONOFORGANOVO HOLDINGS, INC (Form 8-K)

Organovo Holdings Inc.

Organovo Announces Reverse Stock Split

Organovo Holdings Inc.

Organovo Announces Reverse Stock Split (Form 8-K)

Organovo Holdings Inc.

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Organovo Holdings Inc.

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises (Form 8-K)

Organovo Holdings Inc.

Supplemental Prospectus (Form 424B5)

Organovo Holdings Inc.

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company (Form 8-K)

Organovo Holdings Inc.

Quarterly Report for Quarter Ending December 31, 2024 (Form 10-Q)

Organovo Holdings Inc.

Late Filing Notice (Form NT 10-Q)

Organovo Holdings Inc.

Failure to Satisfy Listing Rule (Form 8-K)

Organovo Holdings Inc.

Initial Statement of Beneficial Ownership (Form 3)

Organovo Holdings Inc.

Management Change/Compensation Form 8 K

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member